System and method for discriminating acute and chronic heart failure using an implantable medical device

• US 7,899,522 B1
• Filed: 10/13/2006
• Issued: 03/01/2011
• Est. Priority Date: 10/13/2006
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Park, Euljoon, Koh, Steve, Bornzin, Gene A.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Bays; Pamela M
• Application Number:
  US11/549,569
• Time in Patent Office: 1,600 Days
• Field of Search: 600/508, 600/513, 600/516, 600/517, 600/547, 607/18
• US Class Current: 600/513
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/366 Detecting abnormal QRS complex, e.g. widening
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36521 the parameter being derived from measurement of an electrical impedance
• CPC Class Codes: A61N 1/36585 controlled by two or more physical parameters
• CPC Class Codes: A61N 1/37258 Alerting the patient
• CPC Class Codes: A61N 1/37282 characterised by communication with experts in remote locations using a network

Abstract

Techniques are provided for evaluating heart failure within a patient. In one example, the implantable device detects a decrease, if any, in selected morphological parameters derived from the intracardiac electrogram (IEGM) that are indicative of possible heart failure, such as paced depolarization integrals (PDI) or peak-to-peak amplitudes of QRS-complexes. The device also detects a decrease, if any, in transthoracic impedance, which is also indicative of possible heart failure. Acute heart failure is indicated if there is a decrease in the morphological IEGM parameters but no significant decrease in transthoracic impedance. Chronic heart failure is indicated if there is a decrease in transthoracic impedance but no significant decrease in the morphological IEGM parameters. If both transthoracic impedance and the morphological IEGM parameters are found to be decreasing significantly, the device issues a warning of severe heart failure.

Claims

1. A method for evaluating heart failure within a patient using an implantable medical device, the method comprising:

detecting changes, if any, in cardiac electrical signals indicative of heart failure within the patient;

detecting changes, if any, in transthoracic impedance values indicative of heart failure within the patient; and

distinguishing between acute and chronic heart failure, if occurring within the patient, based on detected changes in the cardiac electrical signals and the transthoracic impedance values, wherein acute heart failure is relatively short term as compared to chronic heart failure;

wherein distinguishing between acute and chronic heart failure within the patient includes (a) generating an indication of acute heart failure if the cardiac signals indicate the presence of heart failure whereas the impedance values exhibit little or no net change in value and (b) generating an indication of chronic heart failure if the impedance values indicate the presence of heart failure whereas the cardiac signals exhibit little or no net change in value.

2. The method of claim 1 wherein the cardiac electrical signals are intracardiac electrogram (IEGM) signals.

3. The method of claim 2 wherein detecting changes, if any, in the IEGM signals includes detecting a decrease in one or more of paced depolarization integrals (PDI) derived from the IEGM, peak-to-peak amplitudes of QRS-complexes within the IEGM, and a maximum slope (Dmax) of the QRS-complex.

4. The method of claim 2 wherein detecting changes, if any, in the IEGM signals includes:

extracting parameters indicative of possible heart failure from the IEGM;

determining a daily value representative of the extracted parameters;

storing the daily values within a multi-day IEGM buffer; and

examining the values of the multi-day IEGM buffer to detect any trends in the daily values indicative of heart failure.

5. The method of claim 4 wherein the multi-day IEGM buffer covers at least 30 days.

6. The method of claim 2 wherein extracting parameters indicative of possible heart failure from the IEGM is performed only while the patient is not active.

7. The method of claim 1 wherein detecting changes, if any, in transthoracic impedance values includes detecting decreases in transthoracic impedance values indicative of pulmonary edema secondary to heart failure.

8. The method of claim 7 wherein detecting changes, if any, in the transthoracic impedance values includes:

detecting transthoracic impedance values while the patient is not active;

identifying the lowest impedance value on a daily basis;

storing the lowest impedance value within a multi-day impedance buffer; and

examining the values of the multi-day impedance buffer to detect any trends in the daily values indicative of pulmonary edema secondary to heart failure.

9. The method of claim 8 wherein the multi-day impedance buffer covers at least 30 days.

10. The method of claim 1 further including:

evaluating the severity of heart failure within the patient based on the impedance values and the cardiac signals.

11. The method of claim 10 further including issuing a warning indicative of the severity of heart failure.

12. The method of claim 1 further including issuing a signal indicative of the type of heart failure, the signal indicating either acute or chronic heart failure.

13. The method of claim 1 further including the step of controlling the storage of diagnostic information indicative of the type of heart failure, the information indicating either acute or chronic heart failure.

14. A system for evaluating heart failure within a patient for use with an implantable medical device, comprising:

an IEGM-based heart failure detection unit adapted to detect heart failure within the patient based on changes, if any, in IEGM signals;

an impedance-based heart failure detection unit adapted to detect heart failure within the patient based on changes, if any, in thoracic impedance; and

a heart failure discrimination unit adapted to distinguish between acute and chronic heart failure within the patient based on output signals provided by the IEGM-based heart failure detection unit and the impedance-based heart failure detection unit, wherein acute heart failure is relatively short term as compared to chronic heart failure;

wherein the heart failure discrimination unit is adapted to (a) generate an indication of acute heart failure if the cardiac signals indicate the presence of heart failure whereas the impedance values exhibit little or no net change in value, and to (b) generate an indication of chronic heart failure if the impedance values indicate the presence of heart failure whereas the cardiac signals exhibit little or no net change in value.

15. The system of claim 14 further including:

a warning controller adapted to generate an indication of the severity of heart failure based on an evaluation of the output signals provided by the IEGM-based heart failure detection unit and the impedance-based heart failure detection unit.

16. A system for evaluating heart failure within a patient for use with an implantable medical device, comprising:

means for detecting changes, if any, in cardiac electrical signals indicative of heart failure within the patient;

means for detecting changes, if any, in transthoracic impedance values indicative of heart failure within the patient; and

means for distinguishing between acute and chronic heart failure within the patient based on detected changes in the cardiac electrical signals and the transthoracic impedance values, wherein acute heart failure is relatively short term as compared to chronic heart failure;

wherein the means for distinguishing between acute and chronic heart failure within the patient includes (a) means for generating an indication of acute heart failure if the cardiac signals indicate the presence of heart failure whereas the impedance values exhibit little or no net change in value and (b) means for generating an indication of chronic heart failure if the impedance values indicate the presence of heart failure whereas the cardiac signals exhibit little or no net change in value.

17. A method for evaluating heart failure within a patient using an implantable medical device, the method comprising:

detecting changes, if any, in cardiac electrical signals indicative of heart failure within the patient;

detecting changes, if any, in transthoracic impedance values indicative of heart failure within the patient;

generating an indication of acute heart failure if the cardiac signals indicate the presence of heart failure whereas the impedance values exhibit little or no net change in value;

generating an indication of chronic heart failure if the impedance values indicate the presence of heart failure whereas the cardiac signals exhibit little or no net change in value, wherein acute heart failure is relatively short term as compared to chronic heart failure; and

evaluating the severity of heart failure within the patient based on the impedance values and the cardiac signals.